Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino an oral minocycline drug for the treatment of moderate to severe acne; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Exelderm cream for antifungal intended for topical use; Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Amzeeq; Zilxi; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children. The company's early stage product candidates include MB-102 for blastic plasmacytoid dendritic cell neoplasm; MB-101 for glioblastoma; MB-104 for multiple myeloma and light chain amyloidosis; MB-106 for B-cell non-hodgkin lymphoma; MB-103 for GBM & metastatic breast cancer to brain; MB-108; MB-105 for prostate and pancreatic cancers; and BAER-101. Its preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and ONCOlogues, and oligonucleotide platform. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.
| Market Cap | Shares Float | Float Held by Institutions % | Shares Outstanding | Shares Authorized | Institutional Own % |
|---|---|---|---|---|---|
| 0.00 M | 92.45 M | 0.44% | 92.45 M | Unavailable | 0.44% |
| Date of Short Interest by FINRA | Shares Sold Short | Short Float % | Insider Own % | Number Institutions Holding Shares |
|---|---|---|---|---|
| 31-Aug-2023 | 0.00 M | 0 | 0.00% | 1 |
No quarterly or yearly financial filing has been filed. This company may be a recent IPO or may have become listed through a special purpose acquisition company (SPAC).
Dilutive convertible shares can impact a stock's price by increasing the number of outstanding shares, potentially reducing the value of existing shares and decreasing the stock price.
Stock Warrants can increase share count when exercised. This dilutions affects earnings per share and potentially reduces stock value and impacting investments.
Shelf Registrations can impact a stock's price by increasing the supply of shares available for sale, potentially lowering demand and decreasing stock price, leading to decreased returns on investors.
Shelf Registrations can impact a stock's price by increasing the supply of shares available for sale, potentially lowering demand and decreasing stock price, leading to decreased returns on investors.
Sign up to see if this company has any shelf registrations pending effect
Registration Statements, which provide information on a company's financials and business plans before a public offering, can impact trading by affecting investor perception and demand for the stock, potentially leading to price changes.
Sign up to see if this company has any registration statements
Registration Statements, which provide information on a company's financials and business plans before a public offering, can impact trading by affecting investor perception and demand for the stock, potentially leading to price changes.
Sign up to see if this company has any registration statements pending effect